Table 1 Baseline demographics and disease characteristics
Baseline characteristics | mITT population (N = 82) |
|---|---|
Median age, years (range) | 60.0 (42, 82) |
Patient age, n (%) | |
 ≥65 | 32 (39.0) |
Gender, n (%) | |
 Male | 43 (52.4) |
 Female | 39 (47.6) |
Baseline ECOG performance status, n (%) | |
 0 | 26 (31.7) |
 1 | 54 (65.9) |
 2 | 2 (2.4) |
Tumor burden increase (screening to pre-dose), n (%) | 60 (73.2) |
 Median, % | 23.1 |
 Range, % | 2.1–317.9 |
MM subtype at baseline, n (%) | |
 IgG | 40 (48.8) |
 IgA | 17 (20.7) |
 IgD | 7 (8.5) |
 Others | 19 (23.2) |
R-ISS stage at baseline, n (%) | |
 I | 23 (28.0) |
 II | 50 (61.0) |
 III | 9 (11.0) |
High-risk cytogenetic abnormalities | 55 (67.1) |
 del 17p13 | 18 (22.0) |
 t(4;14) | 21 (25.6) |
 t(14;16) | 5 (6.1) |
 1q amplification | 53 (64.6) |
Creatinine clearance, mL/min, n (%) | |
 <30 | 3 (3.7) |
 30–<60 | 15 (18.3) |
 ≥60 | 64 (78.0) |
Median time since initial MM diagnosis, years (range) | 3.2 (0.2–13.4) |
Respond to last regimen (≥PR), n (%) | 24 (29.3) |
Median prior regimens (range) | 5 (1–16) |
Prior therapy, n (%) | |
 Lenalidomide | |
  Exposed vs refractory | 82 (100.0) vs 82 (100.0) |
 Bortezomib | |
  Exposed vs refractory | 82 (100.0) vs 82 (100.0) |
 Daratumumab | |
  Exposed vs refractory | 23 (28.0) vs 20 (24.4) |
 Ixazomib | |
  Exposed vs refractory | 28 (34.1) vs 26 (31.7) |
 Carfilzomib | |
  Exposed vs refractory | 6 (7.3) vs 5 (6.1) |
 Pomalidomide | |
  Exposed vs refractory | 10 (12.2) vs 9 (11.0) |
 Prior ASCT | 18 (22.0) |
 Prior CAR-T | 10 (12.2) |